Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis - Two Ends of the Same Spectrum
- PMID: 33996701
- PMCID: PMC8113413
- DOI: 10.3389/fped.2021.665815
Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis - Two Ends of the Same Spectrum
Abstract
Kawasaki disease (KD) and systemic juvenile idiopathic arthritis (sJIA) are two distinct systemic inflammatory diseases of childhood. Each diagnosis is based on criteria, but numerous clinical features are overlapping. As no specific diagnostic tests are available, differentiation between both disease entities can be challenging. Here, we describe the disease course of patients with co-diagnosis of both KD and sJIA (KD/sJIA). All our KD (n = 1765) and sJIA (n = 112) cases were critically reviewed for co-diagnosis of KD/sJIA. Eight KD/sJIA cases were identified and their clinical presentation, treatment regimens, coronary artery outcome and complications are herein described. Each KD/sJIA patient fulfilled diagnostic criteria for KD and for sJIA. Ongoing fever, rash and arthritis were present in each patient. The KD/sJIA patients had recalcitrant KD requiring multiple doses of intravenous immunoglobulin and steroids. Five patients had coronary artery dilatation at KD diagnosis, which resolved in all by 6 weeks. Pericardial effusion was present in 5 patients. One KD/sJIA patient developed macrophage activation syndrome. In conclusion, a small proportion (0.5%) of our KD patients evolved into sJIA, and 7% of our sJIA population presented initially as KD. KD/sJIA patients were characterized by a recalcitrant KD course and a high prevalence of coronary artery dilatation. Patients with co-diagnoses may provide a clue to potentially shared immunopathology in KD and sJIA, leading us to posit that both entities may be part of the same clinical spectrum.
Keywords: fever; interleukin 1; juvenile idiopathic arthritis; kawasaki disease; macrophage activation syndrome; systemic juvenile idiopathic arthritis.
Copyright © 2021 Go, van Veenendaal, Manlhiot, Schneider, McCrindle and Yeung.
Conflict of interest statement
RS provided consultation for Sobi and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Kawasaki Disease-Associated Cytokine Storm Syndrome.Adv Exp Med Biol. 2024;1448:365-383. doi: 10.1007/978-3-031-59815-9_25. Adv Exp Med Biol. 2024. PMID: 39117827 Review.
-
Overlapping clinical features of systemic juvenile idiopathic arthritis and SARS-CoV-2-related multisystem inflammatory syndrome in children.Reumatologia. 2023;61(1):63-70. doi: 10.5114/reum/161185. Epub 2023 Mar 8. Reumatologia. 2023. PMID: 36998579 Free PMC article.
-
Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.Rheumatol Int. 2022 May;42(5):879-889. doi: 10.1007/s00296-021-04980-7. Epub 2021 Sep 7. Rheumatol Int. 2022. PMID: 34491393 Free PMC article.
-
[Clinical analysis of systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms].Zhonghua Er Ke Za Zhi. 2024 Dec 2;62(12):1158-1163. doi: 10.3760/cma.j.cn112140-20240728-00524. Zhonghua Er Ke Za Zhi. 2024. PMID: 39563043 Chinese.
-
Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257. Epub 2015 Apr 4. Expert Rev Clin Immunol. 2015. PMID: 25843554 Review.
Cited by
-
Impact of Kawasaki disease on juvenile idiopathic arthritis in real-world patients: A population-based cohort study.Front Immunol. 2022 Dec 8;13:1025553. doi: 10.3389/fimmu.2022.1025553. eCollection 2022. Front Immunol. 2022. PMID: 36569831 Free PMC article.
-
Advancing multidisciplinary management of pediatric hyperinflammatory disorders.Front Pediatr. 2025 Apr 30;13:1553861. doi: 10.3389/fped.2025.1553861. eCollection 2025. Front Pediatr. 2025. PMID: 40370972 Free PMC article. Review.
-
Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.Int J Mol Sci. 2022 Apr 12;23(8):4268. doi: 10.3390/ijms23084268. Int J Mol Sci. 2022. PMID: 35457086 Free PMC article. Review.
-
An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.J Clin Immunol. 2022 Aug;42(6):1330-1341. doi: 10.1007/s10875-022-01301-w. Epub 2022 Jun 14. J Clin Immunol. 2022. PMID: 35699824 Free PMC article.
-
Kawasaki Disease-Associated Cytokine Storm Syndrome.Adv Exp Med Biol. 2024;1448:365-383. doi: 10.1007/978-3-031-59815-9_25. Adv Exp Med Biol. 2024. PMID: 39117827 Review.
References
-
- Mccrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. . Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the american heart association. Circulation. (2017) 135:e927–99. 10.1161/CIR.0000000000000484 - DOI - PubMed
-
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. (2004) 31:390–2. - PubMed
-
- Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. . Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the pennsylvania systemic onset juvenile arthritis registry (PASOJAR). J Rheumatol. (2008) 35:343–8. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials